Profile

Hi we’re LongeVC!

LongeVC is a venture capital firm focused on advancing an ageless future by investing in early-stage biotech and longevity companies developing breakthrough therapeutics and scalable bio-based material solutions.

Hi we’re IQ Capital!

Hi we’re Corn Lab!

The Corn Lab develops next-generation genome editing and regulation technologies to study DNA repair, hematopoietic stem cell maintenance, and organelle turnover, combining fundamental research with translational projects to advance biological understanding and potential therapies for human genetic diseases.

Hi we’re Anemocyte!

Anemocyte is a Biotech Manufacturing Organization (“BMO”) based in Italy, offering comprehensive development and manufacturing services and providing innovative solutions and products from R&D to GMP. Specialized in the research, development, and production of pDNA and mRNA, Anemocyte brings over 25 years of expertise in innovative therapies and related starting materials.

Hi we’re Genenta!

Genenta is a clinical-stage immuno-oncology company developing Temferon™, a first-in-class hematopoietic stem cell therapy designed to deliver immune-therapeutic payloads within the tumor microenvironment through bone marrow–derived myeloid cells for a durable and targeted anti-tumor response.

Hi we’re 2ndF!

2ndF, a Venture Capital and Private Equity firm, invested in AI-powered cell manufacturing platform that leverages predictive modeling and high-throughput control to engineer human cells and organoids

Hi we’re Cape Fear BioCapital!

Founded in 2024, Cape Fear BioCapital is a North Carolina–based venture fund supporting emerging biotech companies, with investments including an AI-powered cell manufacturing platform that applies predictive modeling and high-throughput control to engineer human cells and organoids for drug discovery, regenerative medicine, and cell therapy.

Hi we’re First Star Ventures!

First Star Ventures invests in entrepreneurs applying frontier technologies like AI and computational biotech to solve real-world problems, including an AI-powered cell manufacturing platform that uses predictive modeling and high-throughput control to engineer human cells and organoids for drug discovery, regenerative medicine, and cell therapy.